A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors

Cancer Discovery
Jaume Capdevila, Josep Tabernero

Abstract

Gastroenteropancreatic neuroendocrine tumors are rare neoplasms; past decades have seen limited research channeled into this area. Recently, 2 placebo-controlled phase III trials using 2 drugs--everolimus and sunitinib--with distinct molecular rationales achieved their principal objective of increasing survival in patients with advanced pancreatic neuroendocrine tumors (PNET). Nonetheless, several questions remain unanswered, notably defining the optimal schedule for integrating these targeted agents with conventional cytotoxics and other treatment options, and identifying appropriate biomarkers for patients with the potential to derive greater benefit. In this article, we analyze the results of the 2 largest studies ever completed in patients with PNETs and discuss the challenges for future drug development in this setting. Sunitinib and everolimus will become new treatment options for patients with PNETs and will be integrated into the complex therapeutic management of this disease. In this review, we summarize the evidence-based data of these drugs as well as the molecular-based science in this setting that will lay the groundwork for future studies.

References

Sep 25, 2002·Proceedings of the National Academy of Sciences of the United States of America·Andrew R TeeJohn Blenis
Dec 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria A KouvarakiJames C Yao
Apr 19, 2005·Genes & Development·Alex Gregorieff, Hans Clevers
Jun 7, 2005·Proceedings of the National Academy of Sciences of the United States of America·Cory M JohannessenKaren Cichowski
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine FaivreEric Raymond
Jan 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeCharles S Fuchs
Feb 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Stefano VoliniaCarlo M Croce
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeCharles S Fuchs
Aug 18, 2006·Nature Reviews. Cancer·David M Sabatini
Sep 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claudia RoldoCarlo M Croce
Oct 10, 2006·American Journal of Physiology. Lung Cellular and Molecular Physiology·Lin ShanMary E Sunday
Jan 8, 2008·The Lancet Oncology·Irvin M ModlinAnders Sundin
Mar 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoJaffer A Ajani
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoDouglas B Evans
Jul 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeCharles S Fuchs
Sep 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoFunda Meric-Bernstam
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew H KulkeMark S Redston
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edoardo MissiagliaAldo Scarpa
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoBertram Wiedenmann
Jun 24, 2010·Endocrine-related Cancer·Dermot O'ToolePhilippe Ruszniewski
Dec 15, 2010·Nature Reviews. Clinical Oncology·Naoko TakebeS Percy Ivy
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group

❮ Previous
Next ❯

Citations

Jan 1, 2014·Cancer Metastasis Reviews·J CapdevilaA Scarpa
Sep 25, 2014·Endocrine-related Cancer·Sebastian KrugPatrick Michl
Dec 3, 2014·Seminars in Diagnostic Pathology·Chanjuan Shi, David S Klimstra
Jul 15, 2016·Cancer Biology & Therapy·Giandomenico RovielloDaniele Generali
Dec 12, 2018·Pancreas·Bhavina D O Batukbhai, Ana De Jesus-Acosta
Feb 6, 2020·Endocrine-related Cancer·Matthias BeyensKen Op de Beeck
Mar 16, 2017·Cancer Science·Masahiro Takikawa, Rieko Ohki

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Claudia RoldoCarlo M Croce
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Edoardo MissiagliaA Scarpa
Annals of Surgical Oncology
James C YaoDouglas B Evans
© 2021 Meta ULC. All rights reserved